Amsterdam 2013 Programme Satellite Meetings Registration Exhibition Virtual Exhibition Hotels Visa Letter Invitation
Search Abstracts by author or title
(results will display both Free Papers & Poster)
Back to Freepaper Session

Small aperture corneal inlay for presbyopia

Session Details

Session Title: Intracorneal inlays for correction of presbyopia

Session Date/Time: Tuesday 08/10/2013 | 08:00-10:30

Paper Time: 08:30

Venue: Main Lecture Hall (Ground Floor)

First Author: : A.Marinho PORTUGAL

Co Author(s): :    M. Freitas               Melles

Abstract Details


To evaluate the efficacy ,safety and adverse events of a small aperture corneal inlay (KAMRA) to treat presbyopia


Hospital Arrįbida Porto Portugal


25 presbyopic patients (age 44 to 61) with healthy eyes were implanted with Kamra inlay in the non dominant eye. The base line refraction of the implanted eye was from +0.75 to -3.50. Simultaneously to the implantation, Lasik was performed (if needed) to aim at a final refraction from plano to -0.75. The implantation was done at a 200 micra depth under a corneal flap or inside a corneal pocket. Distance and near uncorrected vision of the implanted eye were evaluated at day 1,month 1, month 6 and year 1. Corneal topography and visual field testing were also performed.


At day 1 distance uncorrected visual acuity was in all patients between 20/30 and 20/20. The distance uncorrected visual acuity improved with time and was 20/25 or better in all eyes at 6 months. However 2 eyes developed myopic shift at 1 month causing loss of distance uncorrected visual acuity ,that was reverted with increase in topical steroid treatment. The near uncorrected vision was from J3 to J1, being significantly better in eyes with final refraction of –0.75. Near vision also improved with time and exercise. No other adverse events were observed.


Small aperture KAMRA inlay is safe and effective to correct presbyopia. The results show that a final refraction of-0.75 in the implanted eye is important to achieve the desired outcome.

Financial Interest:


loading Please wait while information is loading.